PhotonPharma Inc. Receives Patent for Its Cutting-Edge Cancer Treatment
Innovative Method for Producing Enhanced Immunogenicity in Cancer Treatment
PhotonPharma, a pioneering biotechnology firm specializing in advanced cancer immunotherapies, recently announced that it has been granted U.S. Patent No. 12,280,039 B2. This patent covers an inventive method for producing immunotherapy products that utilize photochemically inactivated cancer cells while retaining important immunogenic properties.
Revolutionary Approach to Cancer Immunotherapy
The technology behind this patent, known as Innocell™, offers a promising advancement in cancer treatment strategies. The use of riboflavin (vitamin B2) as a photosensitizer, combined with ultraviolet light, allows for the inactivation of cancer cells while safeguarding critical tumor antigens. This approach effectively addresses a significant challenge in cancer immunotherapy: presentation of tumor antigens to the immune system to elicit a targeted immune response against the patient's specific tumor.
Key Benefits of the Technology
Product Profile
Cancer cells are rendered incapable of replication yet retain their antigenic properties. This ensures that the resultant product can effectively stimulate a wide-ranging immune response targeted towards the patient's tumor.
Preserved Immunogenicity
Vital surface markers and tumor-associated antigens are preserved, allowing for immune recognition and response. These modified cells have showcased their ability to provoke an immune response in pre-clinical studies.
Scalable Manufacturing Process
The photochemical inactivation is a fast and reproducible process, suitable for large-scale clinical production which is crucial for meeting the demands of therapy rollout.
Applicability Across Cancer Types
This innovative technology has the potential to be applied to various types and stages of cancer, broadening the reach of immunotherapy interventions.
Extensive Preclinical Validation
The patent supports robust preclinical data that verifies the technology's effectiveness:
Tumor Growth Inhibition
Research highlights significant tumor growth reductions in diverse animal models, demonstrating the efficacy of the treatment approach.
Enhanced Survival Rates
Studies show extended survival times in treatment groups when compared to control subjects, indicating a strong therapeutic advantage.
Activation of the Immune System
The technology promotes strong T-cell responses, leading to the formation of immunological memory crucial for long-term patient outcomes.
Alan Rudolph, Ph.D., a board member at PhotonPharma, said, "This patent issuance confirms our innovative methodology in cancer immunotherapy and enhances our intellectual property portfolio as we prepare for clinical trials. Our discovery aims to revolutionize the treatment of recurrent ovarian cancer, providing a promising and safer therapeutic alternative for patients."
Ovarian cancer affects a significant number of women annually, with the National Cancer Institute projecting that 20,890 women will be diagnosed, leading to 12,730 fatalities. Notably, the average five-year relative survival rate stands at 51.6% as observed from 2015 to 2021.
Market Potential and Strategic Importance
The global market for cancer immunotherapy is anticipated to reach between $231 billion and $277 billion by 2031, growing at a compound annual growth rate (CAGR) of 11.9% to 13.6%. This surge is driven by a rising incidence of cancer and an increased adoption of immunotherapeutic methods. PhotonPharma's positioning through this patent places it in a strong competitive position within this rapidly growing field.
Upcoming Clinical Trials
PhotonPharma is set to commence Phase I clinical trials, with a focus on patients suffering from recurrent epithelial ovarian cancer, marking a significant step forward in bringing their innovative treatment to market.
About PhotonPharma Inc.
PhotonPharma is dedicated to crafting pioneering cancer treatments that harness the immune system's capabilities in disease combat. With an emphasis on personalized therapies, the company's flagship product, Innocell™, aims to be a first-in-class solution for various solid organ tumors.
For more details, please visit www.photonpharmaceuticals.com or reach out to:
Raymond Goodrich, PhD
CEO, CSO
PhotonPharma, Inc.
Frequently Asked Questions
What is PhotonPharma's new patent about?
The patent covers a novel method for creating cancer immunotherapy products that utilize inactivated cancer cells to stimulate a robust immune response.
What is Innocell™?
Innocell™ is PhotonPharma's primary product, designed to provide innovative cancer treatments by leveraging the body's immune response against tumors.
How does this technology impact cancer treatment?
This technology has the potential to improve treatment outcomes for various cancer types by enhancing the immune system’s ability to recognize and attack cancer cells.
What stage is PhotonPharma at with their research?
PhotonPharma is gearing up to initiate Phase I trials focusing on recurrent epithelial ovarian cancer, moving closer to bringing their treatment to patients.
Why is this patent significant?
This patent underscores PhotonPharma's innovative approach and strengthens its intellectual property in a competitive market, enhancing its growth potential in immunotherapy.
